Key result
This review evaluates the role of parenteral and oral iron supplementation in patients with heart failure and reduced ejection fraction, providing evidence-based recommendations.
Why the study?
Patients with heart failure and reduced ejection fraction are often iron deficient and anemic, prompting investigation into the role of iron supplementation given the availability of newer parenteral preparations.
Answers are grounded in this paper and cite their sources.
This review evaluates the role of iron supplementation, including parenteral and oral formulations, in patients with heart failure and reduced ejection fraction to provide evidence-based recommendations.
Patients with heart failure and reduced ejection fraction are often iron deficient in part due to the inflammatory nature of heart failure that limits iron absorption. Not surprisingly, these patients are often also anemic. The role of iron replacement in heart failure has been the subject of multiple investigations, in part triggered by the availability of newer, safer, parenteral iron preparations. Specifically, ferric carboxymaltose and ferric derisomaltose have been utilized in multiple heart failure trials. Additionally, there have been several smaller trials using oral iron salts in heart failure. This review investigates the role of iron supplementation in patients with heart failure and reduced ejection fraction including the provision of recommendations based on review of available evidence and consensus statements.
No takes yet. Share an insight, caveat, or question.
Jadoon et al. (2026) conducted a review in Heart failure with reduced ejection fraction. Iron supplementation was evaluated. This review evaluates the role of parenteral and oral iron supplementation in patients with heart failure and reduced ejection fraction, providing evidence-based recommendations.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: